Want to see HK:9995 full AI Analyst Report?
9995 Stock Chart & Stats
HK$119.90
-HK$0.38(-3.04%)
At close: 4:00 PM EST
HK$119.90
-HK$0.38(-3.04%)
Day’s Range― - ―
52-Week RangeHK$57.65 - HK$126.60
Previous CloseN/A
Volume1.38M
Average Volume (3M)6.34M
Market Cap
HK$73.90B
Enterprise ValueHK$61.40B
Total Cash (Recent Filing)HK$2.74B
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)60.2
Beta1.59
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.29
Shares Outstanding208,581,240
10 Day Avg. Volume6,644,676
30 Day Avg. Volume6,343,592
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)9.84
Price to Sales (P/S)10.96
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$126.06Price Target Upside5.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)5.55
Revenue Forecast (FY)HK$7.02B
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryA return to sustained positive EBIT and net margins near 21.8% indicates the business can generate recurring operating profits from current products. Durable margins support reinvestment in R&D and commercialization, improving self-funding capacity and long-term competitiveness over the next several months.
Robust Revenue GrowthVery strong revenue growth (~80% recent growth) reflects accelerating product adoption and market penetration, which drives scale and potential operating leverage. Sustained top-line momentum over 2–6 months reinforces commercial traction and underpins durable margin and cash-generation improvements if execution continues.
Improved Capital EfficiencyLower debt-to-equity and a high ROE suggest the company has improved capital efficiency and reduced leverage strain versus prior periods. This steadier balance sheet enhances financial flexibility to fund growth or absorb shocks, making investment and partnership decisions more durable over the medium term.
Bears Say
Poor Cash ConversionVery low OCF/NI (~0.02) is a structural concern: reported earnings are not converting into cash, limiting internal funding for commercialization, clinical programs, or debt reduction. Over 2–6 months this raises reliance on external financing and creates execution risk for sustaining margins and growth.
Volatile Free Cash Flow HistoryA history of deeply negative and volatile free cash flow undermines long-term operational resilience. Irregular FCF forces strategic trade-offs—delaying investments, raising capital, or cutting costs—which increases execution risk and could impair product rollout or R&D over the coming months.
Earnings & Capital Structure VolatilityLarge swings in profitability and leverage indicate underlying business or execution variability. This persistent volatility reduces predictability for partners and investors, complicates planning for manufacturing and launches, and raises the chance of financing or operational disruptions in the medium term.
RemeGen Co. Ltd. Class H News
9995 FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was HK$57.65 and its highest was HK$126.60 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is HK$73.90B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Aug 25, 2026 which is in 39 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.67 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.67.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of HK$0.67 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.476%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9995
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RemeGen Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
495.23%
12-Months-Change
Fundamentals
Return on Equity
42.27%
Trailing 12-Months
Asset Growth
46.80%
Trailing 12-Months
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
9995 Stock 12 Month Forecast
Average Price Target
HK$126.06
▲(5.14% Upside)
Technical Analysis
Akeso, Inc.
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―